Advanced searches left 3/3

Systemic Lupus Erythematosus - DOAJ

Summarized by Plex Scholar
Last Updated: 27 July 2022

* If you want to update the article please login/register

Detection of neutrophil extracellular traps in patient plasma: method development and validation in systemic lupus erythematosus and healthy donors that carry IRF5 genetic risk

Neutrophil extracellular traps are web-like structures extruded by neutrophils after activation or in reaction to microorganisms. Increased NETs have been linked to COVID-19 disease occurrence, more recently. Although there are scientific and reproducible ways to measure NETs from neutrophils using flow cytometry and immunofluorescence, the accurate measurement of NETs in patient plasma or serum remains a challenge. In this study, blood from patients with SLE, non-genotyped healthy controls, and genotyped healthy controls with either the homozygous risk or non-risk IRF5-SLE haplotype were used. Multiplex ELISA kits from SLE patients and healthy donors with IRF5 genetic risk were able to reveal NETs in plasma samples from SLE patients and healthy donors with IRF5 genotype infusions. The immunofluorescence smear assay is a fast, inexpensive, and quantifiable method of detecting NET detection for small amounts of patient plasma.

Source link: https://doi.org/10.3389/fimmu.2022.951254


Bullous systemic lupus erythematosus in females

Systemic lupus erythematosus is a rare blistering case of systemic lupus erythematosus, typically affecting women of African descent. The acute vesiculobullous eruptions in BSLE typically affect photo-distributed areas, although they can arise in areas that are unrelated to sun exposure. In mild disease with stable underlying systemic lupus erythematosus, first-line treatment with dapsone should be considered. The off-label use of rituximab has been shown to be safe and effective in several refractory cases of BSLE that are not responsive to dapsone, glucocorticoids, or steroid-sparing immunosuppressants, as in this study.

Source link: https://doi.org/10.1097/JW9.0000000000000034


Association of Clinical Manifestations of Systemic Lupus Erythematosus and Complementary Therapy Use in Taiwanese Female Patients: A Cross-Sectional Study

Systemic lupus erythematosus is a chronic systemic autoimmune disease that affects predominantly women in the early years of childbearing years. Patients may require complementary therapies to improve their health and reduce symptoms. According, this research sought to investigate whether complementary therapies may have been related to common medical findings in Taiwanese female patients with SLE. 60. 9% of the 317 female patients with SLE had the same symptoms as 40 years or older, with 60% being 40 years old or older. Renal involvement was strongly linked to the use of probiotics and a visit to a hospital's Chinese medicine department. Conclusions : We discovered that SLE was characterized by various clinical signs due to the use of different complementary therapies. Patients with SLE should have up-to-date knowledge of common complementary therapies and be able to provide evidence-based assistance to patients with SLE.

Source link: https://doi.org/10.3390/medicina58070944


Analysis of Peripheral Blood Basophils in Pediatric Systemic Lupus Erythematosus

We first evaluated circulating basophils in children with pediatric SLE here in this region. In comparison to children with inflammatory/non-rheumatic disorders or children with rheumatic disease, circulating basophils were enumerated by fluorescence-based flow cytometry analysis in children impacted with psLE. This report included 52 pediatric patients from these three groups. In children with pSLE, there was a statistically significant decrease in peripherally circulating basophils, compared to the other two groups of patients.

Source link: https://doi.org/10.3390/diagnostics12071701


Triglycerides as Biomarker for Predicting Systemic Lupus Erythematosus Related Kidney Injury of Negative Proteinuria

Systemic lupus erythematosus-related kidney injury can be predicted by fewer biomarkers. This paper uses an apriori algorithm of association rules to mine the predictive biomarkers for SLE-related kidney injury of negative proteinuria. The number of patients with SLE-related kidney disease, SLEDAI-2K, urine P-CAST, and proteinuria had been elevated in the high-triglycerides group. 0. 72 and 0. 82, respectively, in the area under the ROC curve for triglycerides and triglycerides combined proteinuria. High triglycerides levels in 50% of SLE-related kidney injuries of negative proteinuria can be traced to elevated triglycerides levels. Triglycerides can be a potential marker for predicting SLE-related kidney injury, particularly in SLE-related kidney injury of negative proteinuria. Triglycerides' combined proteinuria could help predict SLE-related kidney disease.

Source link: https://doi.org/10.3390/biom12070945


2-Arachidonoylglycerol Reduces the Production of Interferon-Gamma in T Lymphocytes from Patients with Systemic Lupus Erythematosus

Patients with systemic lupus erythematosus and disease activity have elevated plasma levels of 2-AG. In addition, 2-AG is also able to monitor the formation of type 1 interferon in plasmacytoid dendritic cells from SLE patients, which can be controlled by CB 2 activation. The aim of this research was to determine the effect of 2-AG on T lymphocytes from SLE patients. Methods : peripheral blood mononuclear cells from SLE participants and age- and sex-matched healthy donors were isolated by Ficoll's ultra-gradient centrifugation, respectively. Any other T lymphocyte population, whether SLE or HD, did not modify the cytokine expression of any other T lymphocyte population from either SLE or HD. In Th1 lymphocytes of SLE patients, treatment with both 2-AG and AM630 increased the IFN-u0263 expression. Through CB2 activation, 2-AG is able to modulate type 2 IFN production from CD4+ T lymphocytes from SLE patients.

Source link: https://doi.org/10.3390/biomedicines10071675


Mitochondrial impairment and repair in the pathogenesis of systemic lupus erythematosus

Notably, immune cell activation requires a significant amount of cellular energy that is predominately produced by the mitochondria. SLE prophylaxis and therapy have been published recently, by scientific studies on the normalization of mitochondrial redox balance by mROS scavengers and those investigating defective mitophagy have provided new insight into SLE prophylaxis and therapy. However, the precise mechanism that underpins the cell fate at the molecular level remains unclear, while the precise mechanism underlying the cell fate remains uncertain. This report describes specific mitochondrial functions and pathways that are involved in immune responses, as well as systematically describing how mitochondrial dysfunction contributes to SLE pathogenesis. In addition, we review the potential of new mitochondria-targeting drugs for SLE therapy. A promising start in the quest for effective treatments for systemic autoimmune diseases, particularly SLE.

Source link: https://doi.org/10.3389/fimmu.2022.929520


Systemic lupus erythematosus with trisomy X: a case report and review of the literature

Abstract Background The cause of systemic lupus erythematosus is not entirely clear so far, but the incidence of systemic lupus erythematosus has risen in individuals with elevated X chromosomes. Case presentation We present a 17-year-old Chinese female patient with systemic lupus erythematosus complicated by trisomy X, accompanied by lupus nephritis, pancytopenia, hemolytic anemia, and multiserious effusion.

Source link: https://doi.org/10.1186/s13256-022-03478-5


Clusters of clinical and immunologic features in patients with bullous systemic lupus erythematosus: experience from a single-center cohort study in China

Background of the Lupus systemic lupus erythematosus is a unique subset of systemic lupus erythematosus that is clinically characterized by subepidermal tense vesicles or bullae. Methods We retrospectively reviewed all patients who met the diagnostic criteria for BSLE in our institution from 2015 to 2021. The first sign in five of the BSLE patients, with a median duration of 36 months from SLE onset of 36 months. Any patients with BSLE had extra-cutaneous involvement. SLE disease activity index scores exceeded 5 in 10/12 patients, indicating high disease prevalence. Patients in the BSLE group had significantly higher rates of proteinuria, hematuria, hemolytic anemia, and leukopenia than those in the control group. Conclusions Vesiculobullous lesions may be the first sign and suggest a high incidence of BSLE in patients with BSLE.

Source link: https://doi.org/10.1186/s13023-022-02445-z

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions